Lipocine (NASDAQ:LPCN) Director Purchases $35,613.10 in Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi purchased 15,970 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was purchased at an average price of $2.23 per share, with a total value of $35,613.10. Following the completion of the transaction, the director owned 241,365 shares of the company’s stock, valued at approximately $538,243.95. This trade represents a 7.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Lipocine Price Performance

Shares of NASDAQ LPCN opened at $2.05 on Friday. The stock has a market cap of $16.90 million, a PE ratio of -1.15 and a beta of 0.40. Lipocine Inc. has a 1 year low of $1.81 and a 1 year high of $12.37. The firm has a fifty day moving average price of $2.17 and a 200-day moving average price of $2.73.

Lipocine (NASDAQ:LPCN) last released its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. On average, research analysts expect that Lipocine Inc. will post -1.54 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on LPCN shares. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Lipocine in a research note on Monday, September 21st. Weiss Ratings raised Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP purchased a new position in shares of Lipocine during the first quarter valued at about $998,000. Stempoint Capital LP purchased a new stake in shares of Lipocine in the first quarter worth about $1,282,000. ADAR1 Capital Management LLC bought a new position in Lipocine during the first quarter valued at approximately $185,000. Eversept Partners LP bought a new position in Lipocine during the first quarter valued at approximately $2,357,000. Finally, Exome Asset Management LLC purchased a new position in Lipocine during the 1st quarter valued at approximately $486,000. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.